CORCEPT THERAPEUTICS INC — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Corcept reported Q2 2026 revenue of $256.1M (vs. $194.4M in Q2 2025), driven by Korlym/generic revenue of $208.6M and Lifyorli (approved March 2026) revenue of $47.6M from 1,300+ patients. Net income was $43.0M vs. $35.1M year-over-year. The company raised full-year 2026 revenue guidance to $1.1–$1.2B (previously not stated) and reported cash/investments of $544.6M. Pipeline developments include Lifyorli added to NCCN guidelines, EMA review ongoing, Phase 3 ALS trial planned early 2027, and relacorilant NDA for Cushing's syndrome resubmitted with December 17, 2026 decision date.
Why this rating
Strong Q2 revenue growth (+32% YoY) and new product launch (Lifyorli) represent meaningful business expansion relative to $6.1B market cap. Raised guidance reflects sustained momentum. Phase 3 ALS and regulatory catalysts ahead are material but not transformational at this stage.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.